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The molecular mechanisms behind the health benefits of resveratrol remain enigmatic and controversial. In
this issue of Cell Metabolism, Price et al. establish a clear chemical-genetic connection between SIRT1 and
resveratrol, providing strong evidence that SIRT1 is critical for resveratrol to stimulate mitochondrial biogen-
esis and a switch toward oxidative muscle fibers (Price et al., 2012).A quick PubMed search for articles con-
taining the keyword ‘‘resveratrol’’ gener-
ates more than 4,600 papers. Resveratrol
is a naturally produced polyphenol with
medicinal properties of interest to a
wide range of researchers, health profes-
sionals, and those seeking an alternative
nutriceutical route to healthy aging. Often
mimicking some of the antiaging pheno-
types of calorie restriction (Barger et al.,
2008), the benefits of resveratrol treat-
ment are varied but most revealing in
mice studies where resveratrol improved
metabolic function and reduced inflam-
mation (Lagouge et al., 2006; Pearson
et al., 2008). Not surprisingly, there has
been tremendous effort to uncover the
molecular mechanisms of this compound.
In this issue of Cell Metabolism, Sinclair
and colleagues report a clever chemical-
genetic approach that establishes the
protein deacetylase SIRT1 as a key
mediator of resveratrol action (Price
et al., 2012).
In 2003, Howitz et al. identified resvera-
trol in a high-throughput screen for
effectors of in vitro activity of the NAD+-
dependent deacetylase SIRT1, the
mammalian ortholog of the reported
longevity factor sir2 in yeast and other
organisms (Howitz et al., 2003). In this
assay, resveratrol stimulated the activity
of SIRT1. The potential molecular link
between resveratrol and a longevity pro-
tein such as sir2 was an intoxicating
notion. SIRT1 has been implicated as an
antiaging factor in numerous dysregu-
lated physiologies that include glucose
homeostasis, neurodegeneration, and
mitochondrial integrity (Donmez and
Guarente, 2010). Several cell-based
studies appeared to support the assertion566 Cell Metabolism 15, May 2, 2012 ª2012that resveratrol was a direct in vivo target
of SIRT1 and seemed to reasonably ex-
plain several physiological benefits asso-
ciated with the compound. However, it
was discovered that the apparent activa-
tion of SIRT1 reported by Howitz et al.
was dependent on a fluorescent tag asso-
ciated with the acetylated peptide sub-
strate used in the screen (Borra et al.,
2005; Kaeberlein et al., 2005). These
results added doubt to the conclusion
that resveratrol is a direct activator of
cellular SIRT1 function. Chung and
coworkers added more uncertainty when
they reported recently that resveratrol
directly inhibits cAMP-degrading phos-
phodiesterases (Park et al., 2012).
To establish a clear chemical-genetic
connection between SIRT1 and resvera-
trol, it was essential to demonstrate that
the specific physiological effects of re-
sveratrol are lost when functional SIRT1
is absent. In this issue of Cell Metabolism,
Sinclair and coworkers report several
important advancements in under-
standing the link between mammalian
SIRT1 and resveratrol (Price et al., 2012).
Because SIRT1 is critical for mouse
development, studying the role of resver-
atrol in adult mice is complicated by
severe abnormalities of SIRT1-deficient
mice. Using a tamoxifen-inducible SIRT1
knockout (KO), Price et al. were able to
avoid complications elicited from germ-
line knockouts and study directly the
dependency of resveratrol on functional
SIRT1 in adult mice (Price et al., 2012).
In striking fashion, resveratrol improved
skeletal muscle mitochondrial function
and induced a shift towardmore oxidative
muscle fibers in wild-type (WT) mice fed
a high-fat diet, but no effect was observedElsevier Inc.on adult-inducible SIRT1 KO mice fed
the same diet. Also, high overexpression
of SIRT1 in a transgenic mouse strain
mimicked the effects of resveratrol treat-
ment in skeletal muscle, demonstrating
the requirement of SIRT1 to mediate
resveratrol’s effects. As resveratrol is
known to improve glucose homeostasis,
Price et al. examined whether these
effects were lost in the inducible SIRT1
KO mice. Surprisingly, there was little if
any difference in glucose homeostasis
and liver function between the WT and
inducible KO mouse in response to re-
sveratrol treatment. Price et al. suggest
that this may be due to the incomplete
removal of SIRT1 in the adult-inducible
KO, and/or because the liver response in
SIRT1 KO mice relies on signaling from
other tissues. These are reasonable
explanations, though the possibility that
resveratrol has minimal effects on SIRT1
in the liver remains a possibility.
AMP-activated protein kinase (AMPK)
is a well-established sensor of low meta-
bolic fuel and another reported target of
resveratrol. AMPK-deficient mice exhibit
a blunted response to resveratrol treat-
ments, identifying AMPK as a critical
mediator of resveratrol action (Um et al.,
2010). Price et al. performed experiments
addressing the role of AMPK in resvera-
trol’s action and support a model in which
lower doses of resveratrol stimulate
SIRT1 upstream of AMPK, specifically
via the deacetylation of LKB1, one of the
activating protein kinases of AMPK (Price
et al., 2012). Recently, Park et al. sug-
gested that resveratrol is not directly tar-
geting SIRT1 but instead stimulates the
AMPK pathway through direct inhibition
of cAMP-degrading phosphodiesterases
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cAMP levels and stimulation of a Ca2+-
dependent pathway involving CamKKb
(Park et al., 2012). Some groups suggest
that SIRT1 functions much later in the
pathway, after AMPK stimulates NAD+
production through increased transcrip-
tion of NAD+ synthetic enzymes (Um
et al., 2010). Regardless of the proposed
mechanism, the transcriptional coactiva-
tor PGC1a is the ultimate recipient of the
signaling pathway. Using C2C12 cells,
Price et al. showed that lower doses of
resveratrol increased SIRT1-dependent
phosphorylation of AMPK, while a higher
dose led to SIRT1-independent activation
of AMPK. Interestingly, the two doses dis-
played opposite trends; higher resveratrol
decreased NAD+ and ATP levels, while
the lower dose led to increases in both
metabolites, though the NAD+ change
was not evident until 12 hr. These results
convincingly demonstrate that different
dosages of resveratrol can elicit varied
responses.
Most importantly, the work by Price
et al. provides strong evidence that
SIRT1 is a critical player in mediating the
effects of resveratrol on mitochondrial
biogenesis and the switch to more oxida-
tive muscle fibers (Price et al., 2012).
Given the pleiotropic effects of resvera-
trol, the molecular mechanism remainsin dispute. When and how are SIRT1 and
PDE4 involved in the resveratrol-depen-
dent activation of AMPK? How does
resveratrol concentration differentially
affect the reported targets and their asso-
ciated signaling pathways? A careful time
course analysis of all the implicated
factors is essential. For example, if
SIRT1 is directly activated by resveratrol,
then upon treatment, deacetylation of
LKB1 should precede or coincide with
AMPK phosphorylation. Similarly, does
SIRT1-dependent deacetylation of
PGC1a occur prior to, coincident with,
or after initial AMPK activation? It will be
important to dissect the initial signaling
events from those of the metabolically
reprogrammed state. Increased NAD+
synthesis might to be a long-term adap-
tion to drive sustained sirtuin function or
to replenish NAD+ levels as a result of an
initial surge in sirtuin activity. The results
from Price et al. strengthen the biological
link between resveratrol and SIRT1-
dependent processes, and provide a
backdrop to further studies that resolve
the mechanism.REFERENCES
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Impaired activity of peroxisome proliferator-activated receptor (PPAR)-g coactivator (PGC)-1a has been
implicated in the pathophysiology of several neurodegenerative disorders. In this issue, Da Cruz et al.
(2012) show improvedmuscle function, but not survival, with increased PGC-1a activity in muscle in amouse
model of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis (ALS) is a
progressive neurodegenerative disease
that targets motor neurons in the brainand spinal cord, resulting in muscle weak-
ness, atrophy, and eventual death. In
about 20% of familial ALS cases, thedisease is associated with mutations
in the gene that encodes copper-zinc
superoxide dismutase (SOD1), whichm 15, May 2, 2012 ª2012 Elsevier Inc. 567
